Counterpoint Quantitative Equity ETF (CPAI)

Looking at the Q2 2026 regulatory filings, institutional support for CPAI is clearly expanding with 54 funds holding $306M. Seeing 26 new positions opened against only 3 closures signals that institutional confidence is building, even if retail sentiment remains mixed regarding the fund's short-term volatility.

From a quantitative risk perspective, CPAI presents a fascinating puzzle. While its 5-year beta is elevated at 1.20 against the SandP 500, Morningstar rates its risk-vs-category as Low across periods, backed by a strong Sortino ratio of 1.70. We must prepare models that account for its historical downside capture of 135.5% during sharp market selloffs.

On our desk, the valuation profile is the most compelling aspect. With a portfolio P/E sitting at 13.89x compared to the mid-cap blend peer average of 17.85x, CPAI offers a tangible valuation cushion. However, with long-term earnings growth estimated at 12.72%, we need to weigh that against the macro reality of sticky interest rates.

Watching the macro backdrop, the Fed holding rates at 5.25% to 5.50% through most of 2025 and limited cuts priced for the next year keeps pressure on higher-multiple growth segments. CPAI's low P/E helps, but it lacks the immediate rate-relief tailwind that mid-cap stocks typically crave to re-rate aggressively.

In our technical review, CPAI is currently trading about 7.69% above its 200-day moving average. Even though its performance since inception in 2023 outpaced standard benchmarks like IVV, QQQ, IJH, and AIEQ, the weak risk-adjusted returns and a high beta require tight stop-loss boundaries for tactical allocations.